Nabi scores $540M pact for NicVAX; Kansas University gets vaccine research contract;
> Nabi Biopharmaceuticals has wrapped a licensing deal worth potentially more than $540 million with GlaxoSmithKline for its experimental therapy designed to treat nicotine addiction and prevent smokers who kick the habit from tearing open a fresh pack. Report
The Associated Press details the metoric rise of the vaccine business in recent years, from the days when vaccine research was all but abaondon to the coming golden era of groundbreaking therapies. Report
The National Institutes of Health's National Institute for Allergy and Infectious Disease has granted Kansas University a five-year, $6.85 million research contract to help study how to boost the effectiveness and safety of infectious disease vaccines. Report
And Finally... Vets are suggesting that some dogs get the H3N8--a horse virus that jumped to canines about five years ago. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
